<DOC>
	<DOC>NCT02456129</DOC>
	<brief_summary>This is a study in postmenopausal women to investigate the Drug-drug interaction (DDI) between itraconazole(ITZ) and orally administered vilaprisan; absolute bioavailability using intravenous microtracer dose of [14C]vilaprisan.</brief_summary>
	<brief_title>Study in Postmenopausal Women to Investigate the Drug-drug Interaction (DDI) Between Itraconazole(ITZ) and Orally Administered Vilaprisan; Absolute Bioavailability Using Intravenous Microtracer Dose of [14C]Vilaprisan</brief_title>
	<detailed_description />
	<mesh_term>Itraconazole</mesh_term>
	<mesh_term>Hydroxyitraconazole</mesh_term>
	<criteria>Body mass index (BMI): 18 ≤ BMI ≤ 32 kg/m² Postmenopausal state revealed by: Medical history, if applicable (natural menopause at least 12 months prior to first study drug administration; or surgical menopause by bilateral ovariectomy at least 3 months prior to first study drug administration), in addition: in women &lt; 65 years old, follicle stimulating hormone (FSH) &gt; 40 IU/L Incompletely cured preexisting diseases for which it can be assumed that the absorption, distribution, metabolism, elimination or effects of the study drugs will not be normal Known or suspected liver diseases Clinically relevant findings(e.g. blood pressure, electrocardiogram(ECG); physical and gynecological examination, laboratory examination)</criteria>
	<gender>Female</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Clinical Trial, Phase I</keyword>
</DOC>